The Future of Skin Cancer Detection
Meet DermaSensor: a non-invasive, AI-powered device that provides an immediate, objective result for skin cancer risk.
50% Off for the First 3 Months – Now $199/Month (Regularly $399 for Unlimited Users & Patients)
96% sensitivity for detecting all three common skin cancers ¹
Proprietary, FDA-cleared algorithm provides instant results
First FDA device cleared for primary care use
As Featured In
Bridging the Gap in Skin Cancer Detection: Innovative Solutions for Rapid Diagnosis
Skin cancer is a pervasive and underdiagnosed health concern in the United States, exacerbated by the inefficiencies within the healthcare system. Primary care physicians, who are on the frontline to appropriately treat and triage a host of conditions, have had a lack of adequate diagnostic aids to assess skin lesions. There is an unmet need for tools to improve identification of lesions requiring referral, which may otherwise lead to delayed or missed detection of skin cancer.
Key Features
96% sensitivity for detection across all three common skin cancers¹
Proprietary algorithm yields instant assessment.
Ergonomically designed, wireless, and easy to grip.
Always on, ensuring readiness when needed.
How it Works?
Identify lesions suggestive of skin cancer on the patient
Apply handheld DermaSensor device to the lesion and initiate first recording
Five spectral recordings are taken from the skin lesion to complete one scan
DermaSensor's algorithm analyzes spectral data and delivers assessment in seconds
Hassle-free returns after 90 days.
Month-to-Month & no restocking fees.
Immediate, objective result
for skin cancer risk
Save all of your data
on Cloud storage
Detection rate across all
common skin cancers ¹
Technology
DermaSensor’s tip reflects and records quick bursts of light off the lesion’s cellular and sub-cellular content.
The light is analyzed by the built-in computer to provide information to help physicians assess skin lesions (including melanomas, squamous cell carcinomas, and basal cell carcinomas) to aid in a referral decision.
By examining the difference in light scattering, DermaSensor determines if the skin lesion output is “Monitor” or “Investigate Further,” with the latter result including a 1-10 confidence score for malignancy likelihood.
Elastic Scattering Spectroscopy (ESS) has been validated in 30+ publications on clinical studies for various cancer types. Many studies have shown ESS to provide information that is comparable to histopathologic assessment in the analysis of cellular microscopic structure.
Discover what other practitioners are saying.
© 2024 DermaSensor, Inc. All Rights Reserved.
*Applies to $399 monthly subscription rate only (unlimited users and patients).
Please read the Legal Notice for further details.
View device indications for use, warnings, and precautions (no known contraindications).
Clinical Evidence Available Upon Request
80.0009.4
